   |
  |
Scientific Programme
| Click here for the Accepted Abstracts |
Programme - at - a - Glance
TIME |
|
|||
| MC 2 | MC 3 | |||
| 12.00-19.00 | Registration | |||
| 16.00-19.00 | EUROnet Meeting Hilton, Thalia 1 room |
|||
| 17.00-20.00 | Pre-congress Symposium Blood Trans. update in the Middle East |
Pre-congress Symposium Org. Blood Trans. Serv. Central & East. Eur. |
||
TIME |
|
|||
| Trianti | Mitropoulos | Skalkota | MC 3 | |
| 08.00-19.00 | Registration | |||
| 09.00-10.30 | EP 2 Haemop. Stem Cells |
EP 1 Quality of Evidence |
||
| 10.30-11.00 | Coffee break | |||
| 11.00-12.30 | EP 4 Transfusion Practice |
EP 3 Safe Blood Admin. |
||
| 12.30-14.00 | Lunch break | |||
| break | Sat. Symp. Chiron | |||
| 14.00-15.30 | EP 6 Immunohaematology |
EP 5 Haemostasis |
EP 7 Blood Components |
|
| 15.30-17.00 | Sat. Symp. Pall |
Sat. Symp. Haemonetics |
||
| 18.30-20.00 | Opening Ceremony | |||
| 20.00-21.00 | Welcome Reception in the Exhibition Area | |||
TIME |
|
|||
| Trianti | Mitropoulos | Skalkota | MC 3 | |
| 08.30-17.30 | Registration | |||
| 09.00-10.30 | Plenary Lecture 1 | |||
| 10.30-11.00 | Coffee break | |||
| 11.00-12.30 | PS 1 Apheresis |
PS 3 Immunolo. Reactions |
PS 2 Fresh Frozen Plasma |
|
| 12.30-14.00 | Lunch break Visit to the exhibition and posters | |||
| Sat. Symp. Macopharma |
Sat. Symp. Baxter I |
|||
| 14.00-15.30 | PS 5 Transplantation |
PS 4 Bleeding - Thromb. |
PS 6 Hospital Transfusion |
|
| 15.30-17.00 | PS 7 TTD |
PS 9 Developing trans. |
PS 8 Immunohematology |
|
| 17.00-19.30 | General Excursion | |||
TIME |
|
|||
| Trianti | Mitropoulos | Skalkota | MC 3 | |
| 08.00-18.00 | Registration | |||
| 09.00-10.30 | Plenary Lecture 2 | |||
| 10.30-11.00 | Coffee break | |||
| 11.00-12.30 | PS 10 Promoting Blood Don. |
PS 12 Evid. Based Blood |
PS 11 Emerging Tech. |
|
| 12.30-14.00 | Lunch break Visit to the exhibition and posters | |||
| Sat. Symp. Baxter II |
Sat. Symp. Gambro BCT |
|||
| 14.00-15.30 | PS 15 NATA |
PS 14 Developments |
PS 13 Hemotherapy |
|
| 15.30-16.00 | Tea break | |||
| 16.00-17.30 | PS 17 Risk of Contamin. |
PS 16 Platelet Transfusion |
PS 18 Expending Role |
|
| 17.30-19.00 | Plenary Lecture 3 | |||
| 19.00-19.45 | General Assembly ISBT |
|||
| 20.30 | Banquet Pool Party | |||
TIME |
|
|||
| Mitropoulos | Skalkota | MC 3 | ||
| 08.00-14.00 | Registration | |||
| 09.00-10.30 | Plenary Lecture 4 | |||
| 10.30-11.00 | Coffee break | |||
| 11.00-12.30 | PS 21 Alternatives |
PS 20 Demand and supply |
PS 19 Immune-mediated |
|
| 12.30-13.30 | Pro Con Disc. Autologous Donation |
Pro Con Disc. Post-op Compl. |
Debate Paid Blood Donors |
|
| 13.30-14.00 | Closing Remarks | |||
Words of Welcome Board & Organiz
|
↑ top |
Saturday, July 2, 2005 |
|
| 16.00 - 19.00 | Hilton, Thalia 1 room |
| EUROnet Meeting | |
| 17.00 - 20.00 | |
Pre Congress Symposia |
|
| 17.00 - 20.00 | Room MC2 |
| Blood Transfusion update in Eastern Mediterranean Region | |
| Chair: Faten Moftah, Egypt | |
| 17.00 - 17.10 | |
| INTRODUCTION | |
| F. Moftah (Egypt) | |
| 17.10-17.30 | |
| QUALITY AND SAFETY OF PLASMA DERIVATIVES | |
| A. Padilla (WHO) | |
| 17.30-17.50 | |
| GOOD MANUFACTURING PRACTICE IN BLOOD COMPONENTS | |
| M. El-Ekiaby (Egypt) | |
| 17.50-18.10 | |
| INFRASTRUCTURE AND ORGANIZATION OF BTSS IN EMR | |
| S. Hindawi (Saudi Arabia) | |
| 18.10-18.30 | |
| REGULATION AND LEGISLATION OF BTSS IN EMR | |
| F. Moftah (Egypt) | |
| 18.30-18.50 | |
| PLASMA FRACTIONATION ISSUES IN DEVELOPING ENVIRONMENT | |
| Th. Burnouf (France) | |
| 18.50-20.00 | |
| COUNTRY PRESENTATIONS - 7 SELECTED EMR COUNTRIES | |
| (10 minutes each) |
|
| 17.00 - 20.00 | Room MC3 |
| Organisation of Blood Transfusion Service in Central and Eastern European Countries | |
| Chair: M. Letowska, Poland | |
| I. SHORT PRESENTATIONS FROM: | |
| I. Qendro, Albania | |
| E. Svirnovskaya, Belarus | |
| S. Bakalova, Bulgaria | |
| Z. Ivanovic, Croatia | |
| P. Turek, Czech Republic | |
| K. Baroti - Toth, Hungary | |
| V. Kalibatas, Lithuania | |
| E. Zhiburt, Russian Federation | |
| Each presentation will last approximately 7 - 10 minutes. | |
| II. DISCUSSION: | |
| Various systems of BTS; | |
| Possibilities of cooperation and exchange expirience | |
| between BTSes of different countries of this region; | |
| Possibility of cooperation at laboratory level; | |
| Possibility of cooperation at management level; | |
| Possibility of conducting common scientific projects. |
|
Words of Welcome Board & Organiz
|
↑ top |
Sunday, July 3, 2005 |
|
| 09.00 - 10.30 | Skalkotta Hall |
| SESSION 1: Quality of Evidence in Transfusion Medicine | |
| Chair: F. Décary | |
| 09.00 - 09.30 | |
| 2ED-01-01 STANDARDIZING BLOOD COMPONENTS WOULD ALLOW BETTER MONITORING OF THE EFFECTIVENESS OF TRANSFUSION | |
| D. Davenport (University of Michigan, MI, United States of America) | |
| 09.30 - 10.00 | |
| 2ED-01-02 ARE TRANSFUSION GUIDELINES EVIDENCE BASED? | |
| J.P. AuBuchon (Dartmouth-Hitchcock Medical Center, Lebanon, United States of America) | |
| 10.00 - 10.30 | |
| 2ED-01-03 CLINICAL TRIALS AND SYSTEMATIC REVIEWS | |
| E.C.V. Vamvakas (Canadian Blood Services, Ottawa, Canada) | |
| 09.00 - 10.30 | Mitropoulos Hall |
| SESSION 2: Haemopoietic Stem Cells | |
| Chair: N. Anagnou | |
| 09.00 - 09.30 | |
| 2ED-02-04 BIOLOGY OF STEM CELL MOBILIZATION | |
| T.H. Papayannopoulou (University of Washington, Seattle, United States of America) | |
| 09.30 - 10.00 | |
| 2ED-02-05 STEM CELL TRANSPLANTATION; CORD BLOOD VS PERIPHERAL BLOOD STEM-CELLS | |
| E. Gluckman (Hospital Saint-Luc, Paris, France) | |
| 10.00 - 10.30 | |
| 2ED-02-06 DEVELOPMENTAL PLASTICITY OF THE BONE MARROW DERIVED CELLS | |
| G. Vassilopoulos (Biomedical Research Institute (IIBEAA), Athens, Greece) | |
| 10.30-11.00 | |
| COFFEE BREAK |
|
| 11.00 - 12.30 | Skalkotta Hall |
| SESSION 3: Safe Blood Administration | |
| Chair: H. Askitopoulou | |
| 11.00 - 11.30 | |
| 2ED-03-07 RISK MANAGEMENT IN TRANSFUSION MEDICINE | |
| L. Loukopoulos (NASA Ames Research Centre, Athens, Greece) | |
| 11.30 - 12.00 | |
| 2ED-03-08 THE USE OF HAEMOVIGILANCE DATA TO INCREASE SAFETY IN TRANSFUSION MEDICINE | |
| J. Jorgensen (Aarhus University Hospital, Aarhus, Denmark) | |
| 12.00 - 12.30 | |
| 2ED-03-09 EVOLUTION IN VIRUSSES | |
| R. Eglin (National Blood Service, London, United Kingdom) | |
| 11.00 - 12.30 | Mitropoulos Hall |
| SESSION 4: Transfusion Practice | |
| Chair: A. Dimakopoulou | |
| 11.00 - 11.30 | |
| 2ED-04-10 YOUNG VS OLD RBC UNITS; RHEOLOGY; OXYGEN TRANSPORT | |
| D. Thomas (Swansea NHS Trust, Swansea, United Kingdom) | |
| 11.30 - 12.00 | |
| 2ED-04-11 HOW CLOSE ARE WE TO USING UNIVERSAL RBCS? | |
| M.L. Olsson (Lund University Hospital, Lund, Sweden) | |
| 12.00 - 12.30 | |
| 2ED-04-12 BLOOD VOLUME REPLACEMENT - CRYSTALLOIDS VS COLLOIDS VS FFP | |
| H.J. Dieterich (Germany) | |
| 12.30-14.00 | |
| LUNCH BREAK |
|
Words of Welcome Board & Organiz
|
↑ top |
|
12.30 - 14.00 Satellite Symposium organised by Chiron |
Skalkotta Hall |
| New Insights in HBV Testing of Blood Products | |
| 12.30 - 12.35 | |
| WELCOME AND OPENING | |
| Andrew Heaton, Emeryville, USA | |
| 12.35 - 12.55 | |
| STRATEGIES FOR OPTIMAL DETECTION OF HBV IN DONOR BLOOD | |
| Geno-subtypes, mutants, analytical standards, diagnostic screening efficiency of HBsAg, anti-HBc and HBV-NAT assays | |
| Wolfram Gerlich, Giessen, Germany | |
| 12.55 - 13.20 | |
| IMPACT OF POOLED HBV NAT BLOOD SCREENING IN JAPAN | |
| Disease history, epidemiology, pooled NAT yield and risk reduction, HBV transmission, chimpanzee infection studies | |
| Hiroshi Yoshizawa, Hiroshima, Japan | |
| 13.20 - 13.40 | |
| INTRODUCTION OF HBV NAT SCREENING IN ITALY | |
| Epidemiology, vaccination, experience with IDT-NAT, occult hepatitis B yield cases | |
| Alessandro Zanetti, Milan, Italy | |
| 13.40 - 14.00 | |
| DISCUSSION | |
| Moderators: Angelo Hatzakis, Athens, Greece Nico Lelie, Suresnes, France | |
| 14.00 | |
| CLOSURE | |
Words of Welcome Board & Organiz
|
↑ top |
| 14.00 - 15.30 | Skalkotta Hall |
| SESSION 5: Haemostasis | |
| Chair: T. Mandalaki | |
| 14.00 - 14.30 | |
| 2ED-05-13 PHYSIOLOGICAL MECHANISMS; CLINICAL AND LABORATORY ASSESSMENT | |
| S. Machin (University College, London, United Kingdom) | |
| 14.30 - 15.00 | |
| 2ED-05-14 THE ROLE OF DIAGNOSTIC TESTING TO IDENTIFY CONGENITAL VS ACQUIRED DISORDERS OF HEMOSTASIS AND TO OPTIMIZE THE MANAGEMENT OF PERIOPERATIVE BLEEDING. | |
| G. Despotis (Washington University School of Medicine, St Louis, Missouri, United States of America) | |
| 15.00 - 15.30 | |
| 2ED-05-15 DISSEMINATED INTRAVASCULAR COAGULATION | |
| M. Levi (Academic Medical Center, UvA, Amsterdam, Netherlands) | |
| 14.00 - 15.30 | Mitropoulos Hall |
| SESSION 6: Immunohaematology | |
| Chair: Cr. Navarette | |
| 14.00 - 14.30 | |
| 2ED-06-16 MOLECULAR METHODS IN BLOOD GROUPING | |
| D.J. Anstee (Bristol Inst for Transfusion Sciences, Bristol, United Kingdom) | |
| 14.30 - 15.00 | |
| 2ED-06-17 DEALING WITH IMMUNOLOGICAL REFRACTORINESS TO PLATELET TRANSFUSIONS | |
| M. Contreras (National Blood Service, LondonUnited Kingdom) | |
| 15.00 - 15.30 | |
| 2ED-06-18 THE HLA SYSTEM | |
| G. Stavropoulos (General Hospital 'G. Gennimatas', Athens, Greece) | |
| 14.00 - 15.30 | MC3 |
| SESSION 7: When are Blood Components Clinically Effective; What do We Really Know? | |
| Chair: J. Christakis | |
| 14.00 - 14.30 | |
| 2ED-07-19 PLATELETS | |
| R.P. Rebulla (IRCCS Ospedale Maggiore Policlinico, Milano, Italy) | |
| 14.30 - 15.00 | |
| 2ED-07-20 FFP: APPRAISAL OF THE EVIDENCE FOR THE CLINICAL USE OF FFP | |
| S.J. Stanworth, S.J. Brunskill, C.J. Hyde (National Blood Service, Oxford, United Kingdom) | |
| 15.00 - 15.30 | |
| 2ED-07-21 GRANULOCYTES | |
| S. Leitman (National Institute of Health, Bethesda, United States of America) | |
Words of Welcome Board & Organiz
|
↑ top |
| 15.30 - 17.00 Satellite Symposium organised by Pall Europe |
Skalkotta Hall |
| Safety in Transfusion Medicine - Prion Reduction and Bacteria Detection | |
| Chair: Dr. Roger Eglin, Head of National Transfusion Microbiology Laboratory, National Blood Service, United Kingdom | |
| WELCOME | |
| Allen Ross, President Pall Medical | |
| VCJD AND TRANSFUSION - INCIDENCE, RISK AND NEW TECHNOLOGY INTERVENTIONS | |
| Dr. Roger Eglin, Head of National Transfusion Microbiology Laboratory, National Blood Service, United Kingdom | |
| VALIDATION OF THE PALL LEUKOTRAP® AFFINITY PRION REDUCTION FILTER | |
| Dr Sam Coker, Principle Director, R&D, Pall Corporation, United States of America | |
| BACTERIA TESTING OF PLATELETS - CLINICAL RELEVANCE AND ROUTINE EXPERIENCE WITH PALL EBDS | |
| Dr. Kim Ahn Ngyuen, Medical Director, Blood Centers of the Pacific, United States of America | |
Words of Welcome Board & Organiz
|
↑ top |
| 15.30 - 17.00 Satellite Symposium organised by Haemonetics |
MC3 |
| Automation of Red Cell Washing: A better way to deliver a high impact blood component | |
| CLINCIAL BENEFITS OF WASHED RBC: 2005 AND BEYOND | |
| Dr. Mark Popovsky, Medical Director Haemonetics, United States of America | |
| THE QUALITY OF WASHED RBC FROM THE ACP215 | |
| Dr. Walter Nussbaumer, University hospital of Innsbruck, Austria | |
| THE VALUE OF WASHED RBC FOR CHRONICALLY TRANSFUSED PATIENTS | |
| Dr. Michela Macri, Cardarelli Hospital, Naples, Italy Dr. Mark Popovsky, Medical Director Haemonetics, United States of America |
|
19.00 - 20.00 |
Trianti Hall |
| Opening Ceremony | |
| at the International Conference Centre, Megaron, Athens Concert Hall | |
| 20.00 - 21.00 | Exhibition Area |
| Welcome Reception | |
Words of Welcome Board & Organiz
|
↑ top |
Monday, July 4, 2005 |
|
| 09.00 - 10.30 | Trianti Hall |
| PLENARY LECTURES 1: Impact of the EU Directive | |
| Chair: F. Delaney | |
| 09.00 - 09.30 | |
| M-PL1-01 IS THE LANDSCAPE FOR BLOOD COLLECTION AND DISTRIBUTION CHANGING IN EUROPE? | |
| J.L.K. Koistinen (FRC Blood Service, Helsinki, Finland) | |
| 09.30 - 09.50 | |
| M-PL1-02 ADOPTING THE EU DIRECTIVE: IN FRANCE | |
| Ph. Rouger (INTS, Paris, France) | |
| 09.50 - 10.10 | |
| M-PL1-03 ADOPTING THE EU DIRECTIVE: IN SWEDEN | |
| B. Akerblom (Blood Centre, Uppsala, Sweden) | |
| 10.10 - 10.30 | |
| M-PL1-04 THE EU DIRECTIVE IMPLEMENTED INTO THE LEGAL ACT FOR POLISH BLOOD TRANSFUSION SERVICE | |
| M. Letowska (Inst. of Haematology & Blood Transfusion, Warsaw, Poland) | |
| 10.30 - 11.00 | |
| COFFEE BREAK | |
Words of Welcome Board & Organiz
|
↑ top |
| 11.00 - 12.30 | Mitropoulos Hall |
| PARALLEL SESSION 1: Apheresis | |
| Chair: P. Hoecker, G. Theodosiadis | |
| 11.00 - 11.20 | |
| M-PA-001 MULTICOMPONENT DONATION | |
| T.A. Flesland (Asker and Baerum Hospital, Rud, Norway) | |
| 11.20 - 11.40 | |
| M-PA-002 HEMAPHERESIS GUIDELINES | |
| G. Andreu (EFS, Paris, France) | |
| 11.40 - 12.00 | |
| M-PA-003 THERAPEUTIC APHERESIS | |
| J. Dervenoulas (Greece) | |
| 12.00 - 12.10 | |
| M-PA-004 PREOPERATIVE PLASMA EXCHANGE THERAPY IN PATIENTS UNDERGOING HIGH RISK CARDIAC SURGERY | |
| R. Radovancevic, A.W. Bracey, B. Radovancevic, D.N. Feldman, P.M. Allison, I.D. Gregoric, O.H. Frazier, O.H. Frazier (Texas Heart Institute, Houston, United States of America) | |
| 12.10 - 12.20 | |
| M-PA-005 PHOTOPHERESIS AS MONOTHERAPY IN THE TREATMENT OF CHRONIC GVDH: REPORT OF FIVE CASES | |
| M. Mariano, A. Donelli, R. Anderlini, P. Bresciani, A. Cuoghi, M. De Palma, F. Narni (Servizio di Medicina Trasfusionale, Modena, Italy) | |
| 12.20 - 12.30 | |
| M-PA-006 COLLECTION IN PEDIATRIC PATIENTS: THE APHERESIS UNIT EXPERIENCE OF AO "V.CERVELLO" | |
| F. Buscemi, D. Caselli, R. Mannino, R. Messina, M. Amodeo, S. Cannella, M. Arico, R. Marceno (AO Cervello, UO Medicina Trasfusionale, Palermo, Italy) |
|
| 11.00 - 12.20 | MC3 |
| PARALLEL SESSION 2: Fresh Frozen Plasma | |
| Chairs: F. Moftah, K. Sofroniadou | |
| 11.00 - 11.20 | |
| M-PA-007 ALTERNATIVE METHODS FOR PREVENTION OF INFECTION TRANSMISSION (PATHOGEN INACTIVATION ETC.), COST-BENEFIT CONSIDERATIONS | |
| T.A. Hervig (Haukeland University Hospital, Bergen, Norway) | |
| 11.20 - 11.40 | |
| M-PA-008 CLINICAL USE OF PLASMA IN EUROPE | |
| C. Velati (Ospedale di Sandrio, Sandrio, Italy) | |
| 11.40 - 11.50 | |
| M-PA-009 QUALITY AND STABILITY OF METHYLENE BLUE-TREATED PLASMA PREPARED UNDER WORST CASE CONDITIONS | |
| U. Gravemann, P. Pohler, S. Reichenberg, U. Budde, W.H. Walker, H. Mohr, T.H. Müller (Blood Center of the German Red Cross, Springe, Germany) | |
| 11.50 - 12.00 | |
| M-PA-010 PHOTODYNAMIC INACTIVATION OF HUMAN HEPATITIS B VIRUS IN PLASMA AS REVEALED BY LONG-RANGE PCR | |
| J. Knüver-Hopf, H. Mohr, T.H. Müller (Blood Center of the German Red Cross, Springe, Germany) | |
| 12.00 - 12.10 | |
| M-PA-011 SAFETY OF FRESH FROZEN PLASMA INACTIVATED WITH THE THERAFLEX METHYLENE BLUE SYSTEM (FFP-MB): FOUR YEARS' EXPERIENCE | |
| C. Politis, P. Katsea, S. Hantziara, L. Kavallierou, D. Tsoutsos, N. Anagnostopoulos, G. Gorgolidis, P. Ziroyiannis (G.Gennimatas General Hospital, Athens, Greece) | |
| 12.10 - 12.20 | |
| M-PA-012 CYTOKINE LEVELS IN PATHOGEN-INACTIVATED AND GAMMA-IRRADIATED PLATELET CONCENTRATES | |
| T.O. Apelseth, T.A. Hervig, S. Bjoersvik, Ø. Bruserud (Haukeland University Hospital, Bergen, Norway) |
|
| 11.00 - 12.20 | Skalkotta Hall |
| PARALLEL SESSION 3: Immunologic Reactions to Transfusion | |
| Chairs: M. Popovsky, A. Mougiou | |
| 11.00 - 11.20 | |
| M-PA-013 TRANSFUSION-RELATED ACUTE LUNG INJURY: CURRENT CONCEPTS | |
| M.A.P. Popovsky (Haemonetics Corporation, Braintree, United States of America) | |
| 11.20 - 11.40 | |
| M-PA-014 TRANSFUSION-ASSOCIATED GRAFT VERUS HOST DISEASE: STRATEGIES FOR PREVENTION | |
| L. Corash (Cerus Corporation, Concord, United States of America) | |
| 11.40 - 11.50 | |
| M-PA-015 FOUR-YEAR CUMULATIVE INCIDENCE OF SERIOUS ADVERSE TRANSFUSION EVENTS IN THE QUEBEC HEMOVIGILANCE SYSTEM | |
| P. Robillard, K.I. Nawej (Quebec Public Health Institute, Montreal, Canada) | |
| 11.50 - 12.00 | |
| M-PA-016 REEVALUATION OF TRALI CASES BASED ON THE RECOMMENDED CRITERIA | |
| H. Okazaki, Y. Watanabe, T. Mazda, S. Hashimoto, H. Kamata, K. Ikeda, K. Tadokoro, T. Juji (Japanese Red Cross Central Blood Inst., Tokyo, Japan) | |
| 12.00 - 12.10 | |
| M-PA-017 CAN HAEMOLYTIC TRANSFUSION REACTIONS BE AVOIDED BY BETTER LABORATORY PRACTICE? | |
| D. Stainsby, S.M. Knowles, C. Milkins, H. Jones, H. Cohen (Serious Hazards of Transfusion, Manchester, United Kingdom) | |
| 12.10 - 12.20 | |
| M-PA-018 TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI): CLINICAL CORRELATES AND PATIENT CHARACTERISTICS FROM A RETROSPECTIVE ANALYSIS OF 119 CASES | |
| L.K. Boshkov, J. Logan, L. Podlosky (Oregon Health & Science University, Portland, Oregon, United States of America) | |
Words of Welcome Board & Organiz
|
↑ top |
| 12.30 - 14.00 | |
| LUNCH BREAK, VISIT TO THE EXHIBITION AND POSTERS |
|
| 12.30-14.00 Satellite Symposium organised by Baxter |
Skalkotta Hall |
| Automated Red Cell Collection: Real Life Experience | |
| - programme will be available on site - | |
| 12.30-14.00 Satellite Symposium organised by Macopharma |
Mitropoulos Hall |
| An Innovative Approach for the Reduction of vCJD Transmission in the Blood Supply | |
| BACKGROUND AND EPIDEMIOLOGY OF VCJD | |
| Dr Richard Knight, National CJD Surveillance Unit (NCJDSU), Edinburgh, United Kingdom | |
| DEPLETION OF BLOOD-BORNE TSE INFECTIVITY BY LIGAND ADSORPTION | |
| Dr. Robert G. Rohwer, Director of the Molecular Neurovirology Laboratory, VA Medical Center, University of Maryland, Baltimore, United States of America | |
| VCJD IN TRANSFUSION MEDICINE | |
| Dr Chris Prowse, Research & Development Director, SNBTS R&D Directorate, Edinburgh, United Kingdom | |
Words of Welcome Board & Organiz
|
↑ top |
| 14.00 - 15.00 | Skalkotta Hall |
| PARALLEL SESSION 4: Bleeding - Thrombosis | |
| Chairs: V. Kretschmer, A. Karafoulidou | |
| 14.00 - 14.20 | |
| M-PA-019 BLEEDING TO NEW ANTICOAGULANTS OR ANTIPLATELET AGENTS | |
| M. Samama (Hospital Avicenne, Bobigny, France ) | |
| 14.20 - 14.40 | |
| M-PA-020 NEW ANTICOAGULANTS IN THE TREATMENT OF THROMBOEMBOLISM | |
| A.C. Spyropoulos (Lovelace Medical Center, Albuquerque, Nm, United States of America) | |
| 14.40 - 14.50 | |
| M-PA-021 HOME-MADE AND COMMERCIAL FIBRIN GLUE IN LIVER SURGERY: A COMPARATIVE STUDY | |
| G. Inghilleri, L. Santoleri, A. Aloni, N. Caruso, L. De Carlis, G. Rondinara (Ospedale Niguarda Ca' Granda, Milano, Italy) | |
| 14.50 - 15.00 | |
| M-PA-022 RECOMBINANT FACTOR VIIA : INCREASED MORTALITY WITH UNREGULATED CONTINUOUS USE IN BLEEDING AND COAGULOPATHIC PATIENTS | |
| S. Ganguly, K. Spengel, L. Tillzer, E. Kirkland (University of Kansas Medical Center, Kansas City, United States of America) | |
| 14.00 - 15.20 | Mitropoulos Hall |
| PARALLEL SESSION 5: Transplantation | |
| Chairs: A. Brand, M. Kazakantza | |
| 14.00 - 14.20 | |
| M-PA-023 PERIPHERAL BLOOD STEM CELLS - OLD AND NEW APPLICATIONS | |
| A. Skandali (Hugeria Hospital, Athens, Greece) | |
| 14.20 - 14.40 | |
| M-PA-024 UNRELATED CORD BLOOD TRANSPLANTATION | |
| P. Rubinstein (New York Blood Centre, New York, United States of America) | |
| 14.40 - 14.50 | |
| M-PA-025 TRANSPLANTED STEM CELL APHERESIS PRODUCTS CONTAINING TUMOR CELLS AND PATIENT SURVIVAL | |
| W. Gebauer, I. Barklage (DRK Oldenburg, Oldenburg, Germany) | |
| 14.50 - 15.00 | |
| M-PA-026 LARGE VOLUME VS. STANDARD MONONUCREAR CELL (MNC) HARVESTING FOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION | |
| M. Trkuljic, B. Balint, G. Ostojic, L. Ristic (Military Medical Academy, Belgrade, Serbia) | |
| 15.00 - 15.10 | |
| M-PA-027 ENRICHMENT OF NATURAL KILLER CELLS FROM PERIPHERAL BLOOD AND WHOLE BLOOD DERIVED BUFFY COATS FOR ANTI-TUMOUR THERAPY | |
| R. Moog, U. Schwanke, A. Eggert, U. Köhl (German Red Cross West, Ratingen, Germany) | |
| 15.10 - 15.20 | |
| M-PA-028 INDUCIBLE KNOCKDOWN OF HLA EXPRESSION | |
| C. Figueiredo, A. Seltsam, P.A. Horn, R. Blasczyk (Hannover Medical School, Hannover, Germany) | |
| 14.00 - 15.20 | MC3 |
| PARALLEL SESSION 6: Hospital transfusion committees | |
| Chairs: A.R. Bird, E. Zervou | |
| 14.00 - 14.20 | |
| M-PA-029 WHAT IS THE IMPACT OF AUDITS ON TRANSFUSION PRACTICES? | |
| J.P. AuBuchon (Dartmouth-Hitchcock Medical Center, Lebanon, United States of America) | |
| 14.20 - 14.40 | |
| M-PA-030 INFORMED CONSENT IN TRANSFUSION MEDICINE | |
| A. Maniatis (Henry Dunant Hospital, Athens, Greece) | |
| 14.40 - 15.00 | |
| M-PA-031 REPORTING OF TRANSFUSION ERRORS: ETHICS AND RISKS | |
| P.F.W. Strengers (Sanquin, Amsterdam, The Netherlands) | |
| 15.00 - 15.10 | |
| M-PA-032| YEARS OF SHOT DATA 1996-2004: A VIEW OF TRANSFUSION SAFETY IN THE UK | |
| D. Stainsby, H. Jones, H. Cohen, J. Chapman (Serious Hazards of Transfusion, Manchester, United Kingdom) | |
| 15.10 - 15.20 | |
| M-PA-033 PASSING THE BORDERS: WHEN, HOW AND WHERE | |
| D. Pirc-Tiljak (Croatian Institute of Transfusion Med., Zagreb, Croatia) | |
| 15.30 - 17.10 | Mitropoulos Hall |
| PARALLEL SESSION 7: Transfusion transmitted diseases | |
| Chairs: F. Décary, A. Hatzakis | |
| 15.30 - 15.50 | |
| M-PA-033A STRATEGIES TO REDUCE TRANSFUSION ASSOCIATED SEPTIC RISK | |
| R. Eglin (National Blood Service, London, United Kingom) | |
| 15.50 - 16.10 | |
| M-PA-034 EMERGING PATHOGENS | |
| V. Prowse (SNBTS, Edinburgh, United Kingdom) | |
| 16.10 - 16.30 | |
| M-PA-035 NEW METHODS AND CURRENT TRENDS IN DONOR TESTING (FOR INFECTION) | |
| J.A. Barbara (National Blood Service, London, United Kingdom) | |
| 16.30 - 16.40 | |
| M-PA-036 EVALUATION OF IN VIVO RED BLOOD CELL RECOVERY AFTER PROCESSING WITH A NEW FILTER DESIGNED TO REDUCE PRIONS | |
| E. Nelson, H. Taylor, P. Whitley, T. Lieu (Pall Medical, Covina, California, United States of America) | |
| 16.40 - 16.50 | |
| M-PA-037 COMPARATIVE EFFICACY OF BACTERIAL CULTURE VERSUS PATHOGEN INACTIVATION TO REDUCE THE RISK OF TRANSFUSIONASSOCIATED SEPSIS | |
| C. Lass-Flörl, D. Allersdorfer, M. Rheinschmidt, L. Lin, D. Schönitzer, W. Nussbaumer (University of Innsbruck, Innsbruck, Austria) | |
| 16.50 - 17.00 | |
| M-PA-038 SHOULD HBV NAT BE IMPLEMENTED IN FRENCH BLOOD DONORS | |
| A.A. Assal, J. Coste, P. Morel, M. Maniez, D. Rebibo, C. Cornillot, S. Laperche, J. Pillonel, G. Andreu (EFS Centre Atlantique, Tours, France) | |
| 17.00 - 17.10 | |
| M-PA-039 COMBINED DETECTION OF HEPATITIS C VIRUS CORE ANTIGEN AND ANTIBODY AS AN ALTERNATIVE TO NUCLEIC ACID TESTING IN BLOOD SCREENING | |
| S. Laperche, M.H. Elghouzzi, M. Asso-Bonnet, N. Le Marrec, A. Girault, Y. Piquet, M. Deschaseaux, P. Morel (Institut National Transfusion Sanguine, Paris, France) | |
| 15.30 - 17.00 | MC3 |
| PARALLEL SESSION 8: Immunohematology | |
| Chairs: W.R. Mayr, G. Paterakis | |
| 15.30 - 15.50 | |
| M-PA-040 PARTIAL D AND ITS CLINICAL SIGNIFICANCE | |
| C.G. Gassner (CI for Blood Transfusion & Immunol.Dept, Innsbruck, Austria) | |
| 15.50 - 16.10 | |
| M-PA-041 FLUORESCENCE CYTOMETRY FOR COMPLETELY AUTOMATED IMMUNOHEMATOLOGY TESTING | |
| D. Roback, B. Barclay, D. Hillyer (Emory University School of Medicine, Atlanta, Ga, United States of America) | |
| 16.10 - 16.30 | |
| M-PA-042 NONINVASIVE PRENATAL GENOTYPING ON CELL FREE FETAL DNA IN MATERNAL PLASMA | |
| C.E. van der Schoot (Sanquin Research, Amsterdam, The Netherlands) | |
| 16.30 - 16.40 | |
| M-PA-043 DETERMINATION OF THE AFFINITY OF ANTI-D PRESENT IN THE SERUM OF IMMUNIZED SUBJECTS AND IN ANTI-D IG PREPARATIONS BY A METHOD USING UNLABELED ANTIBODIES | |
| P. Lambin, M. Debbia, Y. Brossard (Institut National de la Transfusion, Paris, France) | |
| 16.40 - 16.50 | |
| M-PA-044 LYOPHILIZED PLATELETS (LYO P) USED FOR THE DETECTION OF HPA ANTIBODIES BY MAIPA ASSAY | |
| D. Rigal (EFS Lyon, Lyon, France) | |
| 16.50 - 17.00 | |
| M-PA-045 RHD (201R 223V) ALLELE CLUSTER ANALYSIS IN DIFFERENT ETHNIC POPULATIONS REFINES RHD PHYLOGENY IN HUMANS BY IDENTIFICATION OF RHD(223V) AND NEW ABERRANT D ALLELES | |
| G.H.M. Grootkerk-Tax, J. van Wintershoven, P.C. Ligthart, C.E. van der Schoot, P.A. Maaskant-van Wijk (Sanquin Blood Bank South West Region, Rotterdam, The Netherlands) | |
| 15.30 - 17.10 | Skalkotta Hall |
| PARALLEL SESSION 9: Developing transfusion strategies | |
| Chairs: H.E. Heier, S. Lakoumenta | |
| 15.30 - 15.50 | |
| M-PA-046 DEVELOPING TRANSFUSION STRATEGY IN SURGERY | |
| J. van der Linden (CHU Brugmann-HUDERF, Brussels, Belgium) | |
| 15.50 - 16.10 | |
| M-PA-047 TRANSFUSION STRATEGIES IN PEDIATRICS | |
| L.C. Luban (Children's National Medical Center, Washington, Dc, United States of America) | |
| 16.10 - 16.30 | |
| M-PA-048 TRANSFUSION TRIGGERS AND THE INFLUENCE OF CELL STORAGE | |
| A. McLellan, D.B.L. McClelland, T.S. Walsh (NHS, Edinburgh, United Kingdom) | |
| 16.30 - 16.40 | |
| M-PA-049 EFFECTS OF RED BLOOD CELL STORAGE ON THERAPEUTIC EFFECTIVENESS IN NEONATAL TRANSFUSION | |
| S. Misso, L. Paesano, M. D'Onofrio, B. Feola, E D'Agostino, G. Fratellanza, G. Amato, S. Formisano, A. Minerva (Hospital San Sebastiano, Caserta, Italy) | |
| 16.40 - 16.50 | |
| M-PA-050 FULLY TESTED FRESH UNREFRIGERATED WHOLE BLOOD USAGE FOR MAJOR SURGERY | |
| S. Finch (Royal Perth Hospital, Perth, Australia) | |
| 16.50 - 17.00 | |
| M-PA-051 TRANSFUSION PRACTICE FOR CORONARY ARTERY BYPASS SURGERY IN GREECE. | |
| S. Lakoumenta, M. Vassili, G. Hatzidimitriou, Th. Asteri, P. Stratigi, S. Kanellas, G. Palatianos (Hellenic Society of Blood Transfusion, Athens, Greece) | |
| 17.00 - 17.10 | |
| M-PA-052 PLATELET TRANSFUSIONS IN NEWBORNS AFFECTED WITH THROMBOCYTOPENIA | |
| S. Misso, B. Feola, M. D'Onofrio, L. Paesano, G. Fratellanza, E D'Agostino, A. Fruggiero, A. Minerva (Hospital San Sebastiano, Caserta, Italy) | |
| 17.00-19.30 | |
| GENERAL EXCURSION (for more information see page 102) | |
Words of Welcome Board & Organiz
|
↑ top |
Tuesday, July 5, 2005 |
|
| 09.00 - 10.30 | Trianti Hall |
| PLENARY LECTURES 2: Communication in Medicine | |
| Chairs: D.J. Anstee, P. Ness | |
| 09.00 - 09.45 | |
| T-PL-05 ETHICAL ASPECTS OF MEDICAL PUBLISHING | |
| R. Schwartz (New England Journal of Medicine, Boston, Ma, United States of America) | |
| 09.45 - 10.30 | |
| T-PL-06 THE ART AND SCIENCE OF MEDICAL WRITING | |
| G. Chrousos (Athens University Medical School, Athens, Greece) | |
| 10.30-11.00 | |
| COFFEE BREAK | |
Words of Welcome Board & Organiz
|
↑ top |
| 11.00 - 12.40 | Trianti Hall |
| PARALLEL SESSION 10: Promoting blood donation | |
| Chairs: G. Thurtell, O. Marantidou | |
| 11.00 - 11.20 | |
| T-PA-053 THE CHANGING FACE OF THE DONOR | |
| N. Mikkelsen (IFBDO/FIODS, Frederiksberg, Denmark) | |
| 11.20 - 11.40 | |
| T-PA-054 DONOR SELECTION THROUGHOUT EUROPE | |
| G.F. Folléa (Etablissement Français du Sang PL, Nantes, France) | |
| 11.40 - 12.00 | |
| T-PA-055 BLOOD DONATION: COMPLICATIONS AND EFFECTS | |
| B. Nilsson Sojka (Dept of Transfusion Medicine, Sweden) | |
| 12.00 - 12.10 | |
| T-PA-056 ESTABLISHING A NATIONAL ADVERSE EVENT REPORTING SYSTEM FOR BLOOD DONORS - A PROSPECTIVE STUDY OF 1.8 MILLION DONOR ATTENDANCES IN ENGLAND AND NORTH WALES | |
| E.A. Caffrey, M. Butler, L. Bissell, M. Bowden, R. Fry (National Blood Service, Cambridge, United Kingdom) | |
| 12.10 - 12.20 | |
| T-PA-057 THE COMMUNITY ROLE IN ENHANCEMENT OF VOLUNTARY, NON - REMUNERATED BLOOD DONATION IN THE NEW MILLENNIUM | |
| A.H AlAmiri (Ministry of Health, Sharjah, United Arab Emirates) | |
| 12.20 - 12.30 | |
| T-PA-058 PROBLEMS AND POSSIBILITIES: RECRUITMENT AND RETENTION OF YOUNG PEOPLE AS BLOOD DONORS | |
| A.H. Misje, H.E. Heier, V. Bosnes (Ulleval University Hospital, Oslo, Norway) | |
| 12.30 - 12.40 | |
| T-PA-059 BLOOD DONOR MAGNETIC CARD: A CHALLENGE FOR AMPLIFICATION OF BOTH FIRST-TIME AND REPEAT BLOOD DONORS AND SAFE BLOOD SUPPLY | |
| K. Farmaki, I. Tsoumari, K. Farmakis, M. Savanos (General Hospital of Corinth, Corinth, Greece) | |
| 11.00 - 12.20 | MC3 |
| PARALLEL SESSION 11: Emerging technologies in transfusion | |
| Chairs: Y. Zhu, A. Mouzaki | |
| 11.00 - 11.20 | |
| T-PA-060 EMERGING TECHNOLOGIES IN TRANSFUSION. DNA BASED ASSAYS | |
| J.S. Coste (Etablissement Français du Sang, Montpellier, France) | |
| 11.20 - 11.40 | |
| T-PA-061 PRENATAL GENOTYPING IN THE EMERGING TECHNOLOGIES IN TRANSFUSION | |
| G. Daniels (National Blood Service, Bristol, United Kingdom) | |
| 11.40 - 11.50 | |
| T-PA-062 HIGH-THROUGHPUT GENOTYPING OF RED CELL AND PLATELET ANTIGENS BY DNA MICROARRAY, A PILOT STUDY | |
| C.E. van der Schoot, S.H.W. Beiboer, G. Cheroutre, T. Wieringa-Jelsma, D. Roos, P.A. Maaskant-van Wijk, J. Jongerius, J.T. den Dunnen, M. de Haas (Sanquin Research at CLB, Amsterdam, The Netherlands) | |
| 11.50 - 12.00 | |
| T-PA-063 EVALUATION OF MOLECULAR WEAK D TYPING IN DAILY PRACTICE 2002-2004; PREVENTION OF MISTYPING PARTIAL D AND IDENTIFICATION OF A NEW WEAK D TYPE | |
| G.H.M. Grootkerk-Tax, L. Warnier, P.C. Ligthart, G. Ponjee, P.A. Maaskant-van Wijk, E.A.M. Beckers (Sanquin Blood Bank South West Region, Rotterdam, The Netherlands) | |
| 12.00 - 12.10 | |
| T-PA-064 NON-DELETIONAL ABO*O ALLELES FREQUENTLY CAUSE BLOOD DONOR TYPING PROBLEMS | |
| A. Seltsam, R. Blasczyk, F.F. Wagner (Hannover Medical School, Hannover, Germany) | |
| 12.10 - 12.20 | |
| T-PA-065 THE PREDICTION OF THE FETUS KELL BLOOD GROUP REDUCES AGGRESSIVE INTERVENTIONS | |
| F. Araujo, F. Monteiro, J.A. Duran, H. Nascimento, C. Pereira, M. Lima, A. Cunha, C. Monteiro, J.R. Storry, J.E. Guimaraes (Hospital São João, Porto, Portugal) | |
| 11.00 - 12.10 | Skalkotta Hall |
| PARALLEL SESSION 12: Evidence Based Blood Transfusion | |
| Chairs: M. Bayik, G. Hatzidimitriou | |
| 11.00 - 11.20 | |
| T-PA-067 EVIDENCE-BASED TRANSFUSION MEDICINE | |
| H.E. Heier (Ullevaal University Hospital, Oslo, Norway) | |
| 11.20 - 11.40 | |
| T-PA-068 ACADEMIC TRAINING PROGRAMMES IN TRANSFUSION MEDICINE IN EUROPE | |
| N. Castelli (General Cantonal Hospital, Lugano, Switzerland) | |
| 11.40 - 11.50 | |
| T-PA-069 TEMPLE STUDY: TRANSFUSION EFFECTS IN MYELODYSPLASTIC PATIENTS, LIMITING EXPOSURE | |
| A.J.G. Jansen, J. van den Bosch, W.C.J. Hop, E.A.M. Beckers, M.R. Schipperus, D.J. van Rhenen (Sanquin Bloodbank South West Region, Rotterdam, The Netherlands) | |
| 11.50 - 12.00 | |
| T-PA-070 A PROGRAM TO REDUCE ALLOGENEIC BLOOD EXPOSURE IN PATIENTS UNDERGOING HIP ARTHROPLASTY: A CLUSTER RANDOMIZED TRIAL | |
| C. Wong, M. Vandervoort, S. Vandervoort, A. Donner, G. Zou, J. MacDonald, J. Freedman, K. Karkouti, S. MacDonald, B. Feagan (Robarts Research Institute, London, Canada) | |
| 12.00 - 12.10 | |
| T-PA-071 USE OF PRE-STORAGE LEUKOREDUCED RED CELLS (LR-RBCS) VS STANDARD RBCS (S-RBCS) IN CARDIAC SURGERY PATIENTS IS ASSOCIATED WITH SIGNIFICANT INTERMEDIATE-TERM (2 - 12 MONTH) SURVIVAL BENEFIT | |
| L.K. Boshkov, C.D. Morris, G. Chien, D. Van Winkle, P. Marshall, A.P. Furnary, G. Grunkemeier, Y-X Wu, R. Reik (Oregon Health & Science University, Portland, Oregon, United States of America) | |
| 12.30-14.00 | |
| LUNCH BREAK, VISIT TO THE EXHIBITION AND POSTERS | |
Words of Welcome Board & Organiz
|
↑ top |
| 12.30 - 14.00 Satellite Symposium organised by Gambro BCT |
Skakotta Hall |
| Delivering innovations that expand your vision of tomorrow | |
| Chair: Dr Markakis (Laiko Hospital, Athens, Greece) | |
| Comparative study of production costs of LBP from whole blood (WB), homologous erythropheresis (E) and combined apheresis (CA) : relevance to define the standing of each collection type | |
| Dr. G. Folléa (EFS du Sang Pays de la Loire, Nantes, France) | |
| Mirasol PRT and blood safety : the potential and practical aspects of pathogen reduction technology | |
| Dr. R.P. Goodrich (Navigant Biotechnologies, Denver, USA) | |
| You can't send blood components on a slow boat to China - or why automation in transfusion is a must | |
| Dr. J. Georgsen (Odense University Hospital, Denmark) | |
| 12.30 - 14.00 Satellite Symposium organised by Baxter |
Mitropoulos Hall |
| The INTERCEPT Blood System for platelets: an established and comprehensive blood safety technology - Limitations of current detection systems for platelet concentrates | |
| 12.30 -12.50 | |
| INTRODUCTION AND CURRENT DILEMMAS OF BACTERIAL DETECTION SYSTEMS | |
| Prof. Erhard Seifried (Chairman), Germany | |
| 12.50 - 13.10 | |
| OUTCOMES AFTER ONE YEAR'S IMPLEMENTATION OF BACTERIAL DETECTION SYSTEMS IN THE US | |
| Prof. Christopher Hillyer, United States of America | |
| 13.10 - 13.30 | |
| OUTCOMES AFTER SEVERAL YEARS' IMPLEMENTATION OF BACTERIAL DETECTION SYSTEMS IN EUROPEAN COUNTRIES | |
| Dr Walter Nussbaumer, Austria | |
| 13.30 - 13.50 | |
| THE INTERCEPT BLOOD SYSTEM: PROVEN CLINICAL SAFETY - 18 MONTHS' EXPERIENCE | |
| Dr Jean-Claude Osselaer, Belgium | |
| 13.50 - 14.00 | |
| PANEL DISCUSSION AND CLOSING REMARKS | |
| Prof. Erhard Seifried (Chairman), Germany | |
Words of Welcome Board & Organiz
|
↑ top |
| 14.00 - 15.00 | MC3 |
| PARALLEL SESSION 13: Hemotherapy in Hemoglobinopathies | |
| Chairs: D. Loukopoulos | |
| 14.00 - 14.20 | |
| T-PA-074 THALASSAEMIA: THE IMPACT ON BLOOD TRANSFUSION SERVICES | |
| C. Politis (G. Gennimatas General Hospital, Athens, Greece) | |
| 14.20 - 14.40 | |
| T-PA-075 SHOULD PATIENTS WITH THALASSEMIA INTERMEDIA BE REGULARLY TRANSFUSED? | |
| A.A. Aessopos, D.F. Farmakis (Athens University Medical School, Athens, Greece) | |
| 14.40 - 14.50 | |
| T-PA-076 S-303 PATHOGEN INACTIVATED RED BLOOD CELLS IN PATIENTS WITH HEMOGLOBINOPATHIES PARTICIPATING IN CHRONIC TRANSFUSION PROGRAMS: PRELIMINARY SAFETY AND EFFICACY RESULTS | |
| M.G.C. Conlan, E. Vichinsky, E. Snyder, L.T. Goodnough, R. Labotka, A. Eder, S.R. Sloan, C. Minniti, J. Lin, L. Corash (Cerus Corporation, Concord, United States of America) | |
| 14.50 - 15.00 | |
| T-PA-077 THE IMPACT OF PRESTORAGE LEUCODEPLETION ON THE IMMEDIATE TRANSFUSION ADVERSE EVENTS OF PATIENTS WITH THALASSAEMIA MAJOR | |
| D. Karakantza, A. Kourakli, A. Mougiou, A. Kougelou, E. Arvanitopoulou, D. Lempoussi, N. Zoumbos, E. Theodori (University Hospital of Patras, Patras, Greece) | |
| 14.00 - 15.00 | Skalkotta Hall |
| PARALLEL SESSION 14: Developments in the safety of plasma derived products | |
| Chairs: T. Burnouf, V. Economou | |
| 14.00 - 14.20 | |
| T-PA-078 VIRAL INACTIVATION / ELIMINATION OF PLASMA DERIVED MEDICINAL PRODUCTS | |
| B.D. Flan (LFB, Courtaboeuf Cedex, France) | |
| 14.20 - 14.40 | |
| T-PA-079 VIRAL SAFETY OF PLASMA PRODUCTS: CURRENT STATUS AND CONSEQUENCES | |
| T. Burnouf (Human Plasma Product Services, Lille, France) | |
| 14.40 - 14.50 | |
| T-PA-080 INTERCEPT PLASMA RETAINS A BROAD SPECTRUM OF PROTEINS NECESSARY FOR HEMOSTASIS WITHOUT THROMBIN GENERATION OR COMPLEMENT ACTIVATION | |
| L. Pinkoski, Y. Singh, L. Corash (Cerus Corporation, Concord, California, United States of America) | |
| 14.50 - 15.00 | |
| T-PA-081 APPLICATION OF THE EUROPEAN DIRECTIVE 2004/33/EC: QUANTIFICATION OF RESIDUAL RBCS IN PLASMA BY FLOW CYTOMETRY | |
| M. Delamaire, R. Tardivel, A. Beauplet, M.C. Le Goff, G. Semana (Etablissement Francais du Sang, Rennes, France) | |
| 14.00 - 15.40 | Mitropoulos Hall |
| PARALLEL SESSION 15: NATA session - Autologous Transfusion | |
| Chairs: K. Messmer, C. Vagianos | |
| 14.00 - 14.20 | |
| T-PA-085 DEVELOPMENT AND TRAINING COURSES FOR CELL SALVAGE OPERATORS | |
| D. Thomas (Swansea NHS Trust / Welsh Blood Service, Swansea, United Kingdom) | |
| 14.20 - 14.40 | |
| T-PA-086 MODERN CONCEPTS OF AUTOLOGOUS HEMOTHERAPY | |
| V. Kretschmer, R. Karger (University Hospital, Marburg, Germany) | |
| 14.40 - 15.00 | |
| T-PA-087 HYPEROXIC HEMODILUTION: A NEW BLOOD-SPARING STRATEGY | |
| J. Meier, A. Pape, O. Habler (Johann Wolfgang Goethe University, Frankfurt Am Main, Germany) | |
| 15.00 - 15.10 | |
| T-PA-088 EFFICACY AND SAFETY OF POSTOPERATIVE REINFUSION OF AUTOLOGOUS SHED BLOOD IN ELECTIVE ORTHOPAEDIC SURGERY PATIENTS. A RANDOMIZED, CONTROLLED PILOT-STUDY | |
| C. So-Osman, R.G.H.H. Nelissen, A. Brand (Sanquin Bloodbank, Leiden, The Netherlands) | |
| 15.10 - 15.20 | |
| T-PA-089 EXPERIENCE WITH AUTOLOGOUS PREDONATION IN ELECTIVE ORTHOPEDIC SURGERY | |
| E. Grouzi (KAT General Hospital, Athens, Greece) | |
| 15.20 - 15.30 | |
| T-PA-090 COLLOID SOLUTIONS AND THEIR ESTABLISHMENT IN CLINICAL PRACTICE | |
| J.P. Panagopoulos (P.G.N.P., Patras, Greece) | |
| 15.30 - 15.40 | |
| T-PA-091 RECOMBINANT HUMAN ERYTHROPOIETIN THERAPY IN CRITICALLY ILL PATIENTS - A DOSE RESPONSE STUDY | |
| D.M. Georgopoulos, D. Matamis, N. Xirouchaki, C. Routsi, A. Michalopoulos, A. Maggina, G. Dimopoulos, E. Zakinthinos, G. Nakos (University Hospital, Heraklion, Greece) | |
| 15.30 - 16.00 | |
| TEA BREAK | |
| 16.00 - 17.20 | Skalkotta Hall |
| PARALLEL SESSION 16: Platelet transfusion | |
| Chairs: D. van Rheenen, A. Travlou | |
| 16.00 - 16.20 | |
| T-PA-092 PLATELET STORAGE; ROOM TEMPERATURE VS REFRIGERATION | |
| K. Hoffmeister (BWH and HMS, Boston, United States of America ) | |
| 16.20 - 16.40 | |
| T-PA-093 THROMBOCYTE IMMUNOLOGY - THE ROLE OF ANTIBODIES RELATED TO TRANSFUSION AND PREGNANCY | |
| A. Husebekk, J. Kjeldsen-Kragh, M.K. Killie, B.S. Skogen (University Hospital of North Norway, Tromsoe, Norway) | |
| 16.40 - 16.50 | |
| T-PA-094 A NEW CONTAINER FOR 9-DAY STORAGE FOR PLATELETS | |
| H.O. Ohto, M. Ezuki, T.I. Ito, K.K. Kawabata, T.O. Ogata (Fukushima Medical University, Fukushima, Japan) | |
| 16.50 - 17.00 | |
| T-PA-095 THE EFFECT OF IRRADIATION ON WHITE CELL REDUCED PLATELET CONCENTRATES, STORED FOR 7 DAYS | |
| P.F. van der Meer, L.A.E. Liefting, A.H. Scholtalbers, R.N.I. Pietersz (Sanquin Blood Bank North West Region, Amsterdam, The Netherlands) | |
| 17.00 - 17.10 | |
| T-PA-096 A NOVEL SYSTEM FOR STORAGE OF POOLED BUFFY COAT PLATELET CONCENTRATES (BC PC) IN A GLUCOSE CONTAINING ADDITIVE SOLUTION (PAS-G) | |
| S. Holme, J.C. Yu, R. Garcez, C. Chong (Pall Life Sciences, Covina, California, United States of America) | |
| 17.10 - 17.20 | |
| T-PA-097 PLATELET TRANSFUSIONS IN PATIENTS ALLOIMMUNISED WITH HPA ANTIGENS ALONE OR TOGETHER WITH HLA ANTIGENS | |
| B. Zupanska, K. Maslanka, M. Uhrynowska, K. Guz (Institute of Haemat.& Blood Transfusion, Warsaw, Poland) | |
| 16.00 - 17.20 | Mitropoulos Hall |
| PARALLEL SESSION 17: Risk of contamination of blood components | |
| Chairs: C. Bianco, M. Parara | |
| 16.00 - 16.20 | |
| T-PA-099 INACTIVATION OF BACTERIA | |
| E.S. Seifried, M.M. Mueller (German Red Cross Blood Donor Service, Frankfurt/main, Germany) | |
| 16.20 - 16.40 | |
| T-PA-100 PREVENTION OF BACTERIAL CONTAMINATION OF BLOOD COMPONENTS | |
| P. Ness (Johns Hopkins, Baltimore, United States of America) | |
| 16.40 - 16.50 | |
| T-PA-101 LOOK BACK STUDIES OF ANTI-HCV NEGATIVE/ HCV RNA POSITIVE BLOOD DONORS IDENTIFIED LOW VIREMIC DONATION NOT DETECTED BY MINI-POOL NAT | |
| E. Brojer, A. Gronowska, M. Letowska, G. Liszewski, D. Kubicka-Russel, P. Radziwon (Institute of Haematology and Blood Trans, Warsaw, Poland) | |
| 16.50 - 17.00 | |
| T-PA-102 COSTS AND EFFECTS OF BACTERIAL CULTURING AND PATHOGEN REDUCTION IN THE NETHERLANDS | |
| M.P. Janssen, C.L. van der Poel (UMCU, Utrecht, The Netherlands) | |
| 17.00 - 17.10 | |
| T-PA-103 BACTERIAL SCREENING OF PLATELET CONCENTRATES TO INCREASE SHELF LIFE TO 7 DAYS USING AN AUTOMATED MICROBIAL DETECTION SYSTEM | |
| C.P. McDonald, J. Colvin, S. McGuane, H. Baklan, P. Mahajan, M. Shahram (National Blood Service, London, United Kingdom) | |
| 17.10 - 17.20 | |
| T-PA-104 EVALUATION OF A NEW SYSTEM FOR AUTOMATED MULTIPLEX NAT BLOOD SCREENING | |
| S.A. Herman, E. Padilla, P. Holland, J. Akers, E. Kyger, Y. Yang, C. Parkhouse (Roche Molecular Systems, Pleasanton, United States of America) | |
| 16.00 - 17.30 | MC3 |
| PARALLEL SESSION 18: The expanding role of the Blood Centre | |
| Chairs: J. Chapman, I. Peristeri | |
| 16.00 - 16.20 | |
| T-PA-106 CORD BLOOD BANKING | |
| P. Rubinstein (New York Blood Centre, New York, United States of America) | |
| 16.20 - 16.40 | |
| T-PA-107 HUMAN TISSUE BANKING | |
| F. Décary (Héna-Québec, Montreal, Canada) | |
| 16.40 - 16.50 | |
| T-PA-108 DIRECTED CORD BLOOD BANKING FOR TRANSPLANTATION | |
| J. Smythe, D.H. Pamphilon, S. Watt (National Blood Service, Oxford, United Kingdom) | |
| 16.50 - 17.00 | |
| T-PA-109 INCREASED YIELD OF MATURE PLATELETS IN CULTURES OF CD34-ENRICHED CORD BLOOD CELLS MAINTAINED AT 39?C | |
| R.L. Lemieux, C. Proulx, N. Dupuis, I. St-Amour, L. Boyer (Hema-Quebec, Sainte-foy, Canada) | |
| 17.00 - 17.10 | |
| T-PA-110 WEAK RHCE EXPRESSION IN A PATIENT WITH NEW POLYMORPHISMS IN RHCE-EXON 5 | |
| A. Doescher, F.F. Wagner, U. Bauerfeind, F. Schunter, E.K. Petershofen (Red Cross Blood Transfusion Service, Oldenburg, Germany) | |
| 17.10 - 17.20 | |
| T-PA-111 MIRASOL® PRT TREATMENT INACTIVATES HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMNCS) | |
| L. Fast, G. DiLeone, J. Li, A. Segers, R.P. Goodrich (Brown University/Rhode Island Hospital, Providence, United States of America) | |
| 17.20 - 17.30 | |
| T-PA112 IMPACT OF TRANSFECTION WITH TOTAL RNA OF K562 CELLS UPON ANTIGEN-PRESENTING, MATURATION AND FUNCTION OF HUMAN DENDRITIC CELLS FROM PBMNCS | |
| L. Gao, H.-H. Fan, X.-X. Nie, Y.-C. Gong, Y.-M. Yang, K.-C. Qian, F. Gao (Transfusion Institute of Shanghai, Shanghai, China) | |
Words of Welcome Board & Organiz
|
↑ top |
| 17.30 - 19.00 | Trianti Hall |
| PLENARY LECTURES 3: Immunotherapy | |
| Chairs: G. Pangalis, P.F.W. Strengers | |
| 17.30 - 18.00 | |
| T-PL3-07 IMMUNOMODULATORY EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) | |
| S. Kaveri (INSERM 4681, Paris, France) | |
| 18.00 - 18.30 | |
| T-PL3-08 IVIG IN AUTOIMMUNE NEUROMUSCULAR DISORDERS | |
| C. Dalakas (National Institutes of Health, Bethesda, Maryland, United States of America) | |
| 18.30 - 19.00 | |
| T-PL3-09 DONOR-LYMPHOCYTE INFUSION: TRANSFUSION IMMUNOTHERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION | |
| H.G. Klein (NIH, Bethesda, United States of America) | |
| 19.00 - 19.45 | MC3 |
| ISBT GENERAL ASSEMBLY | |
| 20.30 | |
| BANQUET POOL PARTY | |
| The Banquet Pool Party will be held at the Hilton Athens, by the swimming pool. | |
| This will be the ideal opportunity to get together with colleagues and enjoy the | |
| great music and entertainment whilst dining. The Organisers will spare no efforts | |
| to justify the reputation of Greek gastronomy and make this evening an unforgettable | |
| event. | |
|
|
| 09.00 - 10.30 | Trianti Hall |
| PLENARY LECTURES 4: Gene therapy | |
| Chairs: S. Takamoto, N. Anagnou | |
| 09.00 - 09.45 | |
| W-PL4-10 GENE THERAPY FOR HAEMOPHILIA | |
| K.J. Pasi (Barts and The London, London, United Kingdom) | |
| 09.45 - 10.30 | |
| W-PL4-11 GENE THERAPY FOR THALASSEMIA: WILL IT BECOME REALITY? | |
| G.S. Stamatoyannopoulos (University of Washington, Seattle, United States of America) | |
| 10.30-11.00 | |
| COFFEE BREAK | |
Words of Welcome Board & Organiz
|
↑ top |
| 11.00 - 12.10 | MC3 |
| PARALLEL SESSION 19: Immune-mediated hematologic disorders | |
| Chairs: G. Daniels, G. Eliopoulos | |
| 11.00 - 11.20 | |
| W-PA-113 PRACTICAL APPROACH TO TRANSFUSION IN AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) | |
| P.H.D. Garratty (American Red Cross Blood Services, Pomona, California, United States of America) | |
| 11.20 - 11.40 | |
| W-PA-114 AUTOIMMUNE NEUTROPENIA | |
| H.A. Papadaki (University Hospital of Heraklion, Heraklion Crete, Greece) | |
| 11.40 - 11.50 | |
| W-PA-115 A RARE CASE OF 'COOMBS NEGATIVE' AUTOIMMUNE HAEMOLYTIC ANAEMIA DUE TO RED CELL AUTO-ANTIBODIES OF IGA CLASS | |
| I.K. Korshavn, A.C. Schmidt-Melbye, H.E. Heier (Ullevaal University Hospital, Oslo, Norway) | |
| 11.50 - 12.00 | |
| W-PA-116 THERAPEUTIC APPROACH TO ALLOIMMUNE NEONATAL NEUTROPENIA DUE TO ANTI HNA-2A ALLOIMMUNIZATION WITH SEVERE AND PROLONGED NEUTROPENIA BUT MILD CLINICAL COURSE: TWO CASE REPORTS | |
| M. Tomicic, M. Starcevic, V. Zach, Z. Hundric-Haspl (Croatian Institute of Transfusion Med., Zagreb, Croatia) | |
| 12.00 - 12.10 | |
| W-PA-117 MALE DONORS FOR THE PRODUCTION OF FRESH FROZEN PLASMA: A SPECIAL ISSUE FOR TRALI PATIENTS | |
| K. Stamoulis, V. Zevgolis, A. Dionisatou, A. Athanasiou, I. Drakou, A. Bramou, E. Stephanidis, S. Vlachakou, E. Economou-Petersen (NCPBP E.Politis, Nikea, Greece) | |
| 11.00 - 12.20 | Skalkotta Hall |
| PARALLEL SESSION 20: Demand and supply of blood and blood products | |
| Chairs: R. O'Charoen, I. Kontopoulou | |
| 11.00 - 11.20 | |
| W-PA-119 MAXIMISING THE BLOOD SUPPLY CHAIN IN TIMES OF SHORTAGE | |
| J.F. Chapman (Blood Stocks Management Scheme, London, United Kingdom) | |
| 11.20 - 11.40 | |
| W-PA-120 TRANSFUSION DURING DISASTER | |
| H.G. Klein (NIH, Bethesda, United States of America) | |
| 11.40 - 11.50 | |
| W-PA-121 REHABILITATION OF BLOOD TRANSFUSION SERVICE IN AZERBAIJAN | |
| C.D. Asadov, G.A. Huseynov, A.B. Hagiyev (Institute of Hematology and Transfusiolo, Baku, Azerbaijan) | |
| 11.50 - 12.00 | |
| W-PA-122 UPDATING OF THE RUSSIAN LAW 'CONCERNING THE DONATION OF BLOOD AND BLOOD COMPONENTS' | |
| E. Zhiburt, P. Reizman, A. Vecherko (Federal Blood Center, Moscow, Russian Federation) | |
| 12.00 - 12.10 | |
| W-PA-123 TYPES OF BLOOD BANKS IN TURKEY AND STEPS TOWARD CENTRALIZATION | |
| M. Sönmezoglu, M. Bayik, I. Working group (Marmara University Hospital, Istanbul, Turkey) | |
| 12.10 - 12.20 | |
| W-PA-124 CONTROVERSIAL CLINICAL QUESTIONS CONSIDERED IN A MEDICAL OPINION FORUM BY PHYSICIANS FOR THE ADVANCEMENT OF TRANSFUSION MEDICINE (PATM) | |
| R.L. Jones (New York Blood Center, New York, New York, United States of America) | |
| 11.00 - 12.40 | Mitropoulos Hall |
| PARALLEL SESSION 21: Alternatives to allogeneic transfusion | |
| Chair: F. Décary, C. Tsatalas | |
| 11.00 - 11.20 | |
| W-PA-126 IMPACT OF EPO TREATMENT ON TRANSFUSION REQUIREMENTS IN MYELODYSPLASIA | |
| C. Gardin (Hopital Avicenne, APHP, Univ. Paris 13, Bobigny, France) | |
| 11.20 - 11.40 | |
| W-PA-127 CAN IRON ADMINISTRATION REDUCE PERIPARTUM BLOOD TRANSFUSION | |
| C. Breymann (University of Zurich, Zurich, Switzerland) | |
| 11.40 - 12.00 | |
| W-PA-128 IRON THERAPY IN ORTHOPAEDIC SURGERY | |
| P. Beris (Geneva University Hospital, Geneva, Switzerland) | |
| 12.00 - 12.10 | |
| W-PA-129 MULTIPLE ERYTHROCYTAPHERESIS IN THERAPY OF HEREDITARY HEMOCHROMATOSIS | |
| V. Rehacek (Charles University Hospital, Hradec Kralove, Czech Republic) | |
| 12.10 - 12.20 | |
| W-PA-130 DONORS ANAEMISATION AND IRON DEPLETION AFTER THE DONATION OF 2 UNITS OF RBC BY APHERESIS | |
| G. Inghilleri, L. Santoleri, B. Bonisoli, P. Verducci, M.T. Marceca, E. Fonti, L. Mancini (Ospedale Niguarda Ca' Granda, Milano, Italy) | |
| 12.20 - 12.30 | |
| W-PA-131 HFE MUTATIONS FREQUENCY AND THE ROLE OF H63D MUTATION ON IRON OVERLOAD IN A BLOOD DONORS POPULATION IN ITALY | |
| C. Velati, L. Fomiatti, G. Garozzo, T. Lombardo, E. D'Agostino, D. Testa, O. Prinoth, F. Chiavilli, G. Barillari, P. Fugiani (Sondrio Hospital, Sondrio, Italy) | |
| 12.30 - 12.40 | |
| W-PA-132 ALTERATIONS OF CD43 EXPRESSION IN TRANSFUSIONDEPENDENT MYELODYSPLASTIC SYNDROMES | |
| D. Kyriakou, A.V. Karadonta, K. Karakousis, E. Kyriakou, G. Karras, M. Alexandrakis, D. Kyriakou, N. Stathakis (University Hospital of Larisa, Larisa, Greece) | |
Words of Welcome Board & Organiz
|
↑ top |
| PRO-CON DISCUSSIONS | |
| Chair: G. Palatianos, S Sourmelis | |
| 12.30 - 13.30 | Skalkotta Hall |
| DOES BLOOD TRANSFUSION INCREASE POST-OP COMPLICATIONS? | |
| Chair: G. Palatianos | |
| YES A. Brand (Sanquin Blood Bank, South West, Leiden, The Netherlands) | |
| NO S. Vamvakas (Canadian Blood Service, Ottawa, Canada) | |
| 12.30 - 13.30 | Mitropoulos Hall |
| IS PREDEPOSIT AUTOLOGOUS DONATION WORTHWHILE? | |
| Chair: S. Sourmelis | |
| YES S.M. Kasper (Klinikum Bremerhaven, Bremerhaven, Germany) | |
| NO P.H. van der Linden, CHU Brugmann-HUDERF, Brussels, Belgium | |
Words of Welcome Board & Organiz
|
↑ top |
| 12.30 - 13.30 | MC3 |
| DEBATE: Paid blood donors: are they necessary? | |
| Chairs: Marcela Contreras & Lenka Walterova | |
| 12.30 - 12.40 | |
| GLOBAL OVERVIEW ON VOLUNTARY BLOOD DONATION | |
| N. Dhingra (WHO, Geneva, Switzerland) | |
| 12.40 - 12.50 | |
| THE CASE FOR PAID BLOOD/PLASMA DONATIONS | |
| J.Bult (PPTA, Brussels, Belgium) | |
| 12.50 - 13.00 | |
| THE CASE FOR NON-PAID VOLUNTARY BLOOD/PLASMA DONATIONS | |
| C. van der Poel (Sanquin, Amsterdam, The Netherlands) | |
| 13.00 - 13.10 | |
| ISSUES RELATING TO VOLUNTARY NON REMUNERATED DONATION IN EASTERN EUROPE | |
| V. Hafner (CDS-SHP, Hellerup, Denmark) | |
| 13.10 - 13.30 | |
| DEBATE | |
| 13.30 - 14.00 | Trianti Hall |
| CLOSING REMARKS | |